PharmaEssentia Receives Health Canada Approval for BESREMi® to Treat Adults with Polycythemia Vera
PharmaEssentia Corporation, a Taiwan-based global biopharmaceutical company specializing in the development of innovative biologic therapies for hematology and oncology, has announced that its wholly owned subsidiary, FORUS Therapeutics Inc., has received a Notice of Compliance (NOC) from Health Canada for BESREMi® (ropeginterferon alfa-2b). The approval authorizes the use of BESREMi® for the treatment of adults living with polycythemia vera (PV), marking an important regulatory milestone for the company and expanding treatment options for patients with this rare chronic blood cancer in Canada.
Following the regulatory approval, PharmaEssentia stated that BESREMi® is expected to become commercially available across Canada in the coming weeks. The launch will provide Canadian hematologists with access to a next-generation interferon therapy specifically approved for polycythemia vera, offering an additional therapeutic option for patients requiring long-term disease management.
Expanding Access to Treatment for Polycythemia Vera
Polycythemia vera is a rare, chronic myeloproliferative neoplasm characterized by the excessive production of red blood cells within the bone marrow. The abnormal increase in red blood cells causes the blood to become thicker and more viscous, making it more difficult to circulate through blood vessels and increasing the likelihood of potentially life-threatening complications.
Patients with polycythemia vera face an elevated risk of developing blood clots, which can lead to serious cardiovascular events such as deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. Over time, the disease may also progress to more advanced hematologic disorders, including myelofibrosis or acute myeloid leukemia, both of which are associated with significantly poorer prognoses.
In addition to these serious medical complications, many patients experience persistent symptoms that substantially affect their quality of life. Fatigue, headaches, dizziness, night sweats, itching (particularly after warm baths or showers), visual disturbances, and abdominal discomfort resulting from an enlarged spleen are among the most commonly reported symptoms.
Because polycythemia vera is considered a lifelong condition, treatment strategies focus on reducing the risk of thrombosis, controlling blood cell counts, alleviating symptoms, and slowing disease progression whenever possible.
BESREMi® Offers a Next-Generation Interferon Approach
BESREMi® (ropeginterferon alfa-2b) represents a newer generation of interferon therapy developed specifically for patients with polycythemia vera. Unlike earlier interferon formulations that often required more frequent administration and were sometimes associated with tolerability challenges, BESREMi® has been engineered to provide prolonged activity, allowing for less frequent dosing while maintaining sustained therapeutic effects.
The therapy works by modulating the immune system and targeting the abnormal blood-forming stem cells responsible for the excessive production of red blood cells. In addition to controlling hematologic parameters, interferon therapy has demonstrated the ability to reduce the burden of disease-associated genetic mutations, offering the potential for long-term disease modification in some patients.
Clinical studies supporting the approval of BESREMi® have demonstrated durable hematologic responses, improvements in molecular markers of disease, reduction in symptom burden, and a favorable safety and tolerability profile. These characteristics have contributed to the therapy’s adoption in multiple international markets as an important treatment option for adults living with polycythemia vera.
Health Canada Approval Represents an Important Milestone
The Notice of Compliance granted by Health Canada allows PharmaEssentia and its Canadian subsidiary, FORUS Therapeutics Inc., to begin commercializing BESREMi® throughout the country.
The approval represents another step in the company’s ongoing global expansion strategy as it seeks to broaden access to its hematology portfolio in international markets.
For Canadian physicians treating patients with polycythemia vera, the availability of a therapy specifically approved for this indication provides an additional evidence-based treatment option that can be incorporated into individualized patient management strategies.
The company expects commercial distribution to begin within the coming weeks, enabling eligible patients to access the therapy following reimbursement and formulary processes where applicable.
Company Leadership Highlights Benefits for Patients
Commenting on the approval, Ko-Chung Lin, Ph.D., Founder and Chief Executive Officer of PharmaEssentia, described the Health Canada decision as an important achievement for both the company and the Canadian medical community.
He noted that BESREMi® has demonstrated durable hematologic and molecular responses during clinical development while also reducing disease-related symptoms and maintaining a favorable safety and tolerability profile.
According to Dr. Lin, the company is committed to working closely with hematologists, healthcare providers, patient organizations, and other stakeholders across Canada to ensure that patients living with polycythemia vera gain timely access to the newly approved therapy.
He emphasized PharmaEssentia’s broader mission of delivering innovative biologic medicines that address unmet medical needs within hematology and oncology.
Experts Welcome Expanded Treatment Options
The approval has also been welcomed by members of Canada’s hematology community.
Dr. Shireen Sirhan, President of the Canadian Myeloproliferative Neoplasms Group, Vice-President (Research) of the Quebec Research Group for Chronic Myeloid Leukemia and Myeloproliferative Neoplasms (GQR-LMC-NMP), and hematologist at Jewish General Hospital and McGill University in Montreal, highlighted the importance of expanding treatment choices for patients with polycythemia vera.
She explained that PV is a chronic myeloproliferative neoplasm requiring continuous long-term management to minimize complications, reduce the risk of thrombosis, and effectively control disease-related symptoms.
According to Dr. Sirhan, the availability of BESREMi® represents an important advancement for both physicians and patients because interferon therapy specifically approved for polycythemia vera has been anticipated within the Canadian myeloproliferative neoplasm community for many years.
She noted that the approval reflects ongoing progress in the treatment of myeloproliferative disorders and supports a more personalized approach to patient care by providing physicians with additional therapeutic options tailored to individual clinical needs.
Supporting Individualized Long-Term Disease Management
Treatment decisions for polycythemia vera are often influenced by several factors, including patient age, thrombotic risk, symptom burden, blood counts, underlying genetic features, treatment goals, and overall health status.
As scientific understanding of myeloproliferative neoplasms has evolved, clinicians have increasingly emphasized individualized treatment strategies rather than relying on a single standard approach for all patients.
The introduction of BESREMi® into the Canadian market provides healthcare professionals with another option that may be appropriate for patients requiring long-term disease control while aiming to reduce complications and improve quality of life.
The therapy’s demonstrated ability to produce sustained hematologic and molecular responses may also contribute to broader treatment objectives beyond simple blood count control.
Strengthening PharmaEssentia’s Global Hematology Portfolio
The Canadian approval further expands PharmaEssentia’s international presence in hematologic oncology and reinforces the company’s strategy of bringing innovative biologic therapies to patients with rare blood disorders.
Headquartered in Taiwan, PharmaEssentia has focused its research and development efforts on leveraging proven scientific principles to develop next-generation biologics addressing unmet needs in hematology and oncology.
The commercialization of BESREMi® in Canada through FORUS Therapeutics Inc. represents another milestone in the company’s ongoing efforts to broaden global access to its therapies.
With Health Canada’s approval of BESREMi®, adults living with polycythemia vera in Canada are expected to gain access to an additional treatment option designed specifically for the long-term management of this rare chronic blood cancer. The therapy’s demonstrated ability to deliver durable hematologic and molecular responses, reduce symptom burden, and maintain a favorable safety profile positions it as an important addition to the evolving treatment landscape for polycythemia vera.
As commercial availability begins in the coming weeks, PharmaEssentia will work alongside healthcare providers, hematologists, and other stakeholders to support patient access across Canada. The approval also underscores continued progress in the management of myeloproliferative neoplasms, reflecting ongoing advances in developing therapies that not only control disease but also support more individualized and comprehensive approaches to patient care.
About PharmaEssentia
PharmaEssentia Corporation (TWSE: 6446), headquartered in Taipei, Taiwan, is a global and rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in hematology, oncology, and immunology, with one approved product and a diversifying pipeline.
Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung, Taiwan. For more information about PharmaEssentia Corp visit the website, LinkedIn or X (formerly Twitter).
About Polycythemia Vera (PV)
Polycythemia vera (PV) is a cancer originating from a disease-initiating stem cell in the bone marrow resulting in a chronic increase of red blood cells, white blood cells and platelets. PV may result in cardiovascular complications such as thrombosis and embolism, and often transforms to secondary myelofibrosis or leukemia. While the molecular mechanism underlying PV is still subject of intense research, current results point to a set of acquired mutations, the most important being a mutant form of JAK2.
About BESREMi® (ropeginterferon alfa-2b-njft)
Ropeginterferon alfa-2b-njft is currently FDA-approved and marketed as BESREMi® for the treatment of adults with polycythemia vera (PV). The Company is seeking a ropeginterferon alfa-2b-njft label expansion to include ET and has submitted an sBLA with the U.S. FDA.
BESREMi® holds orphan drug designation in the United States for the treatment of polycythemia vera (PV) in adults. It has received regulatory approval in over 40 countries, including from the European Medicines Agency (2019), the U.S. Food and Drug Administration (2021), the Pharmaceuticals and Medical Devices Agency in Japan (2023), and Health Canada (2026).